- Home
- About
- Team
- Today's Market
- Premium
- Research it
- Outlook
- Portfolio
- Mobile
- Trust Equitymaster
- Help
- Free Reports
MEMBER'S LOGINX
| Login Failure | ||||||||
|
||||||||
| Sign Up | Forgot Password? | ||||||||
- Home
- Stock Quote
- Sector Info (pharmaceuticals)
- Indian Pharma
Indian Pharma Stocks 
Here are the latest stock price details of India's top Indian Pharma stocks. For more detailed updates, read our Indian Pharma sector report and check the latest Indian Pharma sector results.
| SCRIP | BSE PRICE (Rs) | NSE PRICE (Rs) | CHART | MORE INFO |
|---|---|---|---|---|
| AARTI DRUGS | 586.15 0.48% | 584.90 -0.28% | More Info
|
|
| AJANTA PHARMA | 953.10 -1.53% | 954.10 -1.42% | More Info
|
|
| ALEMBIC PHARMA | 538.60 -1.57% | 539.55 -0.90% | More Info
|
|
| BIOCON LTD | 615.85 1.48% | 616.15 1.70% | More Info
|
|
| CADILA HEALTHCARE | 312.35 0.26% | 311.90 0.03% | More Info
|
|
| CIPLA | 539.20 -0.40% | 539.65 -0.28% | More Info
|
|
| DIVIS LABORATORIES | 1,588.50 0.88% | 1,587.85 0.83% | More Info
|
|
| GLENMARK PHARMA | 579.00 0.45% | 579.15 0.36% | More Info
|
|
| INDOCO REMEDIES | 176.40 1.41% | 174.95 1.07% | More Info
|
|
| IPCA LABS | 800.55 -1.10% | 804.85 -0.42% | More Info
|
|
| J.B.CHEMICALS | 320.20 2.28% | 321.05 2.13% | More Info
|
|
| LUPIN LTD | 763.25 -1.02% | 763.10 -1.01% | More Info
|
|
| NATCO PHARMA | 570.35 -0.56% | 569.80 -0.93% | More Info
|
|
| NIFTY 50 | Not Listed | 10,604.35 -0.34% | More Info
|
|
| ORCHID PHARMA LTD | 3.24 0.62% | 18.90 -2.83% | More Info
|
|
| PANACEA BIOTECH | 160.55 0.91% | 161.75 0.68% | More Info
|
|
| PIRAMAL ENTERPRISES | 2,173.05 0.18% | 2,179.60 0.13% | More Info
|
|
| S&P BSE SENSEX | 35,352.61 -0.41% | Not Listed | More Info
|
|
| STRIDES PHARMA SCIENCE | 402.90 -1.20% | 404.10 -1.04% | More Info
|
|
| SUN PHARMA | 414.35 -0.18% | 413.65 -0.24% | More Info
|
|
| TORRENT PHARMA | 1,765.15 0.35% | 1,763.35 -0.01% | More Info
|
|
| WOCKHARDT LTD. | 392.25 0.51% | 392.15 0.65% | More Info
|
BSE prices: February 19, 2019 (Close) NSE prices: February 19, 2019 (Close)
Indian Pharma Stocks Update
The NIFTY PHARMA Index was at 8,543.6 (down 0.4%). The index is down 17.1% over the last 30 days. And over the last 1 year, it has lost 9.1%.
Within the Indian Pharma sector, the top gainers were J.B.CHEMICALS (up 2.3%) and BIOCON LTD (up 1.5%). On the other hand, ALEMBIC PHARMA (down 1.6%) and AJANTA PHARMA (down 1.5%) were among the top losers.
Meanwhile, the benchmark NIFTY 50 was at 10,604.4 (down 0.3%).
|
| |
Today's Market
Sensex Ends 146 Points Lower; IT and Power Stocks Drag(Closing)
Indian share markets witnessed selling pressure during closing hours and ended their trading session marginally lower.Sectoral indices ended on a mixed note with realty stocks.
Related Views on News
NATCO PHARMA Announces Quarterly Results (3QFY19); Net Profit Down 26.7% (Quarterly Result Update)
Feb 14, 2019 | Updated on Feb 14, 2019For the quarter ended December 2018, NATCO PHARMA has posted a net profit of Rs 2 bn (down 26.7% YoY). Sales on the other hand came in at Rs 6 bn (down 1.0% YoY). Read on for a complete analysis of NATCO PHARMA's quarterly results.
IPCA LABS Announces Quarterly Results (3QFY19); Net Profit Up 51.7% (Quarterly Result Update)
Feb 14, 2019 | Updated on Feb 14, 2019For the quarter ended December 2018, IPCA LABS has posted a net profit of Rs 2 bn (up 51.7% YoY). Sales on the other hand came in at Rs 9 bn (up 10.3% YoY). Read on for a complete analysis of IPCA LABS's quarterly results.
DIVIS LABORATORIES 2017-18 Annual Report Analysis (Annual Result Update)
Jan 1, 2019 | Updated on Jan 1, 2019Here's an analysis of the annual report of DIVIS LABORATORIES for 2017-18. It includes a full income statement, balance sheet and cash flow analysis of DIVIS LABORATORIES. Also includes updates on the valuation of DIVIS LABORATORIES.
ALEMBIC PHARMA 2017-18 Annual Report Analysis (Annual Result Update)
Dec 21, 2018 | Updated on Dec 21, 2018Here's an analysis of the annual report of ALEMBIC PHARMA for 2017-18. It includes a full income statement, balance sheet and cash flow analysis of ALEMBIC PHARMA. Also includes updates on the valuation of ALEMBIC PHARMA.
Lupin: US market Declines Due to Higher Base Effect of FY17 (Quarterly Results Update - Detailed)
Feb 9, 2018Price erosion in generic US drugs continues but seems to be bottoming out.
More Views on NewsMost Popular
The RCom Bankruptcy: 5 Lessons for Smallcap Investors(Profit Hunter)
Feb 7, 2019Managements of companies can create or ruin their fortunes. Why is management quality such an important factor in valuing businesses? Read on to find out...
The One Real Estate Stock to Buy Now(The 5 Minute Wrapup)
Feb 13, 2019The real estate sector is ready to make a comeback. This is the stock to consider buying.
How We Pick the Most Profitable Stocks from the Portfolios of Super Investors(The 5 Minute Wrapup)
Feb 8, 2019This is the trick to following super investors and not losing money.
Small Caps Under Seige: Could This Be A Once-in-a-Decade Wealth Creating Opportunity?(Profit Hunter)
Feb 14, 2019Don't let the dark clouds hovering over small caps scare you into hiding; it will rain gold as sentiments recover. Indeed, there is a blood bath. And if you are a first time investor, the correction is deep enough to scare you out of markets.
Don't Be Afraid of the Market; Buy Stocks Like This One(The 5 Minute Wrapup)
Feb 14, 2019During this tough period in the market, a contrarian approach holds huge potential upside for this Smart Money Secrets stock.
More|
| |
S&P BSE HEALTHCARE
Feb 19, 2019 (Close)
S&P BSE HEALTHCARE 5-YR ANALYSIS
COMPARE COMPANY
OTHER USEFUL LINKS
MARKET STATS
ABOUT EQUITYMASTER
Since 1996, Equitymaster has been the source for honest and credible opinions on investing in India. With solid research and in-depth analysis Equitymaster is dedicated towards making its readers- smarter, more confident and richer every day. Here's why hundreds of thousands of readers spread across more than 70 countries Trust Equitymaster.
FREE NEWSLETTERS
PREMIUM PRODUCTS
QUICK LINKS
APPS
FOLLOW
Copyright © Equitymaster Agora Research Private Limited.
Whitelist | Refer | Terms | Privacy | Contact | About | Sitemap
Equitymaster Agora Research Private Limited (Research Analyst) 103, Regent Chambers, Above Status Restaurant, Nariman Point, Mumbai - 400 021. India.
Telephone: +91-22-61434055. Fax: +91-22-22028550. Email: info@equitymaster.com. Website: www.equitymaster.com. CIN:U74999MH2007PTC175407
All rights reserved. Any act of copying, reproducing or distributing this newsletter whether wholly or in part, for any purpose without the permission of Equitymaster is strictly prohibited and shall be deemed to be copyright infringement.
LEGAL DISCLAIMER: Equitymaster Agora Research Private Limited (Research Analyst) bearing Registration No. INH000000537 (hereinafter referred as 'Equitymaster') is an independent equity research Company. Equitymaster is not an Investment Adviser. Information herein should be regarded as a resource only and should be used at one's own risk. This is not an offer to sell or solicitation to buy any securities and Equitymaster will not be liable for any losses incurred or investment(s) made or decisions taken/or not taken based on the information provided herein. Information contained herein does not constitute investment advice or a personal recommendation or take into account the particular investment objectives, financial situations, or needs of individual subscribers. Before acting on any recommendation, subscribers should consider whether it is suitable for their particular circumstances and, if necessary, seek an independent professional advice. This is not directed for access or use by anyone in a country, especially, USA, Canada or the European Union countries, where such use or access is unlawful or which may subject Equitymaster or its affiliates to any registration or licensing requirement. All content and information is provided on an 'As Is' basis by Equitymaster. Information herein is believed to be reliable but Equitymaster does not warrant its completeness or accuracy and expressly disclaims all warranties and conditions of any kind, whether express or implied. Equitymaster may hold shares in the company/ies discussed herein. As a condition to accessing Equitymaster content and website, you agree to our Terms and Conditions of Use, available here. The performance data quoted represents past performance and does not guarantee future results.
SEBI (Research Analysts) Regulations 2014, Registration No. INH000000537.